Herpes Zoster (Shingles) - Pipeline Review, H2 2015
Summary
Global Markets Directs, ‘Herpes Zoster (Shingles) - Pipeline Review, H2 2015, provides an overview of the Herpes Zoster (Shingles)s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Herpes Zoster (Shingles) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Herpes Zoster (Shingles) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Herpes Zoster (Shingles) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Herpes Zoster (Shingles)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Herpes Zoster (Shingles) Overview 7
Therapeutics Development 8
Pipeline Products for Herpes Zoster (Shingles) - Overview 8
Pipeline Products for Herpes Zoster (Shingles) - Comparative Analysis 9
Herpes Zoster (Shingles) - Therapeutics under Development by Companies 10
Herpes Zoster (Shingles) - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Herpes Zoster (Shingles) - Products under Development by Companies 15
Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development 16
Astellas Pharma Inc. 16
Beijing Minhai Biotechnology Co., Ltd 17
Epiphany Biosciences, Inc. 18
Foamix Pharmaceuticals Ltd. 19
GlaxoSmithKline Plc 20
Merck & Co., Inc. 21
NAL Pharmaceuticals Ltd. 22
Spider Biotech 23
TSRL, Inc. 24
Herpes Zoster (Shingles) - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
acyclovir - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
amenamevir - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
FV-100 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GSK-1437173A - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
herpes zoster vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
NAL-3221 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NAL-3223 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SB-105A10 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
TSR-087 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
V-212 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
valomaciclovir stearate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Herpes Zoster (Shingles) - Recent Pipeline Updates 50
Herpes Zoster (Shingles) - Dormant Projects 55
Herpes Zoster (Shingles) - Discontinued Products 56
Herpes Zoster (Shingles) - Product Development Milestones 57
Featured News & Press Releases 57
Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain 57
Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial 57
Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied 58
Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN 58
Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint 59
Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant 59
Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles 60
Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles 60
Apr 09, 2013: Zoster Vaccine Effective Against Incident Herpes Zoster and Post-herpetic Neuralgia in Older US Population, Cohort Study Finds 61
Jul 18, 2012: Agenus Announces Initiation of Phase III Clinical Trial of GSKs Herpes Zoster Vaccine Candidate in Immunocompromised Patients 62
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65
List Of Tables
List of Tables
Number of Products under Development for Herpes Zoster (Shingles), H2 2015 8
Number of Products under Development for Herpes Zoster (Shingles) - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Late Stage Development, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Comparative Analysis by Unknown Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Herpes Zoster (Shingles) - Pipeline by Astellas Pharma Inc., H2 2015 16
Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 17
Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences, Inc., H2 2015 18
Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015 19
Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H2 2015 20
Herpes Zoster (Shingles) - Pipeline by Merck & Co., Inc., H2 2015 21
Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd., H2 2015 22
Herpes Zoster (Shingles) - Pipeline by Spider Biotech, H2 2015 23
Herpes Zoster (Shingles) - Pipeline by TSRL, Inc., H2 2015 24
Assessment by Monotherapy Products, H2 2015 25
Number of Products by Stage and Target, H2 2015 27
Number of Products by Stage and Mechanism of Action, H2 2015 29
Number of Products by Stage and Route of Administration, H2 2015 31
Number of Products by Stage and Molecule Type, H2 2015 33
Herpes Zoster (Shingles) Therapeutics - Recent Pipeline Updates, H2 2015 50
Herpes Zoster (Shingles) - Dormant Projects, H2 2015 55
Herpes Zoster (Shingles) - Discontinued Products, H2 2015 56
List Of Figures
List of Figures
Number of Products under Development for Herpes Zoster (Shingles), H2 2015 8
Number of Products under Development for Herpes Zoster (Shingles) - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Early Stage Products, H2 2015 13
Assessment by Monotherapy Products, H2 2015 25
Number of Products by Top 10 Targets, H2 2015 26
Number of Products by Stage and Top 10 Targets, H2 2015 26
Number of Products by Top 10 Mechanism of Actions, H2 2015 28
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 28
Number of Products by Top 10 Routes of Administration, H2 2015 30
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 30
Number of Products by Top 10 Molecule Types, H2 2015 32
Number of Products by Stage and Top 10 Molecule Types, H2 2015 32
